Revolution Medicines Stock News

Although US stocks closed mostly lower on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the

Although US stocks closed sharply higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they vie

Pipeline of Development-Stage RAS(ON) Inhibitors to be Highlighted in Four Presentations in “Targeting the RAS Oncogene” Session, as well as Presentations in “Chemistry to the Clinic” and “C

Although US stock futures traded lower this morning amid rising Russia-Ukraine concerns, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the co

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, to

REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that the company will participate in the Cowen 42 nd Annual Health Care Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71, compared to year-ago quarter

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ: RVMD ) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71, compared to year-ago quarter EPS of $0.52. The stock has a 52-week-high of $50.88 and a 52-week-low of $18.07. At the end of the last trading period, Revolution Medicines closed at $18.92. According to UBS, the prior rating for Amedisys Inc (NASDAQ: AMED ) was changed from Sell to Neutral. For the fourth quarter, Amedisys had an EPS of $1.18, compared to year-ago quarter EPS of $1.49. At the moment, the stock has a 52-week-high of $292.97 and a 52-week-low of $122.12. Amedisys closed at $160.24 at the end of the last trading period. For Sunstone Hotel Investors Inc (NYSE: SHO ), Evercore ISI Group upgraded the previous rating of In-Line to Outperform. At the moment, the stock has a 52-week-high of $13.91 and a 52-week-low of $9.93. Sunstone Hotel Invts closed at $10.58 at the end of the last trading period. Wedbush upgraded the previous rating for Logitech International SA (NASDAQ: LOGI ) from Neutral to Outperform.

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -9.23% and 15.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the

Revolution Medicines press release (NASDAQ:RVMD): Q4 GAAP EPS of -$0.71 misses by $0.07.Revenue of $9.46M (+8.1% Y/Y) misses by $0.49M.

RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Recently Nominated

RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Recently Nominated

Revolution Medicines, Inc. (RVMD) CEO Mark Goldsmith on Q4 2021 Results - Earnings Call Transcript